This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Hypersensitivity, Allergic Rhinitis, Allergic Conjunctivitis or Seasonal Allergy
and you are
between 18 and 65
years old
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

The purpose of this 2-year study is to assess the sustained clinical efficacy and safety of 300 IR/day of a sublingual solution of birch pollen allergen extract starting 4 months prior to the birch pollen season and continuing over the birch pollen season compared with placebo for reduction of rhinoconjunctivitis-related symptoms and anti-allergy medication usage.

Provided treatments

  • Biological: Placebo
  • Biological: Birch pollen allergen extract

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01731249. The sponsor of the trial is Stallergenes Greer and it is looking for 574 volunteers for the current phase.
Official trial title:
A Randomised, Double-blind, Placebo-controlled, Multi-national, Phase IIIb Study to Assess the Sustained Clinical Effect and Safety of Sublingual Immunotherapy Administered as Birch Pollen Extract Solution at a Dose of 300 IR Once Daily to Patients Suffering From Birch Pollen-induced Rhinoconjunctivitis